OrbiMed Advisors Picked Viewray Inc. (NASDAQ:VRAY) Shares

0
365
SONY DSC

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Viewray Inc. (NASDAQ:VRAY) reported that OrbiMed Advisors has picked up 9,866,102 of common stock as of 2017-03-21.

The acquisition brings the aggregate amount owned by OrbiMed Advisors to a total of 9,866,102 representing a 17.7% stake in the company.

For those not familiar with the company, ViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed.

A glance at Viewray Inc. (NASDAQ:VRAY)’s key stats reveals a current market capitalization of 377.33 million based on 38.23 Million shares outstanding and a price at last close of $7.16 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2017-01-18, Bansal picked up 62,597 at a purchase price of $3.17. This brings their total holding to 70,104 as of the date of the filing.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Viewray Inc. (NASDAQ:VRAY) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.